XTL Biopharmaceuticals has agreed to pay $7.5 million upfront and up to $126.5 million in cash and shares to DOV Pharmaceutical to license development rights to bicifadine as a treatment for neuropathic pain. Bicifadine has been evaluated in 15 clinical trials, including two trials in patients suffering from acute (non-neuropathic) pain, where Bicifadine demonstrated statistically significant efficacy.
- see the release on the licensing pact
DOV formulates new development strategy. Report
DOV CEO resigns in shakeup. Report